| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
National Cancer Institute National Institutes of Health Bethesda 14, Maryland
Data are reported on 821 synthetic compounds which failed the CCNSC primary screens. Most of the materials were tested against Sarcoma 180, Adenocarcinoma 755 and Leukemia L-1210. Cell culture cytotoxicity results for these materials are included.
1 Chief, Cancer Chemotherapy National Service Center.
2 Biologist, Screening Section, Cancer Chemotherapy National Service Center.
3 Present address: Division of Research Grants, National Institutes of Health.
4 Acting Chief, Drug Evaluation Branch, Cancer Chemotherapy National Service Center.
5 Arthur D. Little, Inc., Cambridge, Massachusetts.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |